Page 6 - Flipbook

Kokorovic et al

19. Freedland SJ, Kane CJ, Amling CL, et al. Delay of radical prostatectomy and risk of biochemical progres- 30. Boevé LMS, Hulshof MCCM, Vis AN, et al. Effect on survival of androgen-deprivation therapy alone
sion in men with low-risk prostate cancer. J Urol 2006;175:1298-302. https://doi.org/10.1016/ compared to androgen-deprivation therapy combined with concurrent radiation therapy to the prostate in
S0022-5347(05)00646-4 patients with primary bone metastatic prostate cancer in a prospective randomized clinical trial. Eur Urol
20. Boorjian S, Bianco F, Scardino P, et al. Does the time from biopsy to surgery affect biochemical 2019;75:410-8. https://doi.org/10.1016/j.eururo.2018.09.008
recurrence after radical prostatectomy? BJU Int 2005;96:773-6. https://doi.org/10.1111/j.1464- 31. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castrate-resistant prostate
410X.2005.05763.x cancer. N Engl J Med 2018;378:2465-74. https://doi.org/10.1056/NEJMoa1800536
21. Pisansky TM, Hunt D, Gomella LG, et al. Duration of androgen suppression before radiotherapy for 32. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate
localized prostate cancer: Radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol cancer. N Engl J Med 2018;378:1408-18. https://doi.org/10.1056/NEJMoa1715546
2015;33:332-9. https://doi.org/10.1200/JCO.2014.58.0662 33. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in non-metastatic, castrate-resistant prostate cancer.
22. Gupta N, Bivalacqua TJ, Han M, et al. Evaluating the length of time from diagnosis to surgery in N Engl J Med 2019;380:1235-46. https://doi.org/10.1056/NEJMoa1815671
patients with unfavorable intermediate-risk to very-high risk clinically localized prostate cancer. BJU Int 34. Simcock R, Thomas TV, Mercy CE, et al. COVID-19: Global radiation oncology’s targeted response for
2019;124:268-74. https://doi.org/10.1111/bju.14659 pandemic preparedness. Clin Transl Rad Onc 2020 [Epub ahead of print]. https://doi.org/10.1016/j.
23. Reichard CA, Nyame YA, Sundi D, et al. Does time from diagnosis to treatment of high- or very-high- ctro.2020.03.009
risk prostate cancer affect outcome? BJU Int 2019;124:282-9. https://doi.org/10.1111/bju.14671 35. Zheng MH, Boni L, Fingerhut A, et al. Minimally invasive surgery and the novel coronavirus outbreak:
24. Kumar S, Shelley M, Harrison C, et al. Neo-adjuvant and adjuvant hormone therapy for local - Lessons from China and Italy. Ann Surg 2020 [Epub ahead of print]. https://doi.org/10.1097/
ized and locally advanced prostate cancer. Cochrane Database Sys Rev 2006;CD006019. SLA.0000000000003924
https://doi.org/10.1002/14651858.CD006019.pub2 36. Romero-Laorden N, Lozano R, Jayaram A, et al. Phase 2 pilot study of the prednisone to dexamethasone
25. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 vs 8-month neoadjuvant hor- switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on
monal therapy before radical prostatectomy: Biochemical and pathological effects. J Urol 2001;166:500-7. abiraterone plus prednisone (SWITCH study). Br J Cancer 2018;119:1052-9. https://doi.org/10.1038/
https://doi.org/10.1016/S0022-5347(05)65971-X s41416-018-0123-9
26. Parker C, Clarke NW, Cook A, et al. LBA49_PR - Timing of radiotherapy (RT) after radical prostatectomy 37. Curtis JR. The importance of addressing advance care planning and decisions about do-not-resuscitate
(RP): First results from the RADICALS RT randomized controlled trial (RCT) [NCT00541047]. Ann Oncol orders during the novel coronavirus-2019 (COVID-19). JAMA 2020 [Epub ahead of print]. https://doi.
2019;30:v883-4. https://doi.org/10.1093/annonc/mdz394.042 org/10.1001/jama.2020.4894
27. Vale CL, Brihoum M, Chabaud S, et al. Adjuvant or salvage radiotherapy for the treatment of localized 38. Weiner AB, Conti RM, Eggener, SE. National economic conditions and patient insurance status predict
prostate cancer? A prospectively planned aggregate data meta-analysis. Ann Oncol 2019;30:v883. prostate cancer diagnosis rates and management decisions. J Urol 2016;195:1383-9. https://doi.
https://doi.org/10.1093/annonc/mdz394.041 org/10.1016/j.juro.2015.12.07
28. James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with
hormone therapy. N Engl J Med 2017;377:338-51.https://doi.org/10.1056/NEJMoa1702900 Correspondence: Dr. Ricardo Rendon, Department of Urology, Dalhousie University, Halifax, NS,
29. Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumor for newly diagnosed, meta- Canada; Ricardo.Rendon@Dal.Ca
static prostate cancer (STAMPEDE): A randomized controlled phase 3 trial. Lancet 2018;392:2353-66.
https://doi.org/10.1016/S0140-6736(18)32486-3

168 CUAJ • June 2020 • Volume 14, Issue 6